The Top 5 Biosimilars Articles for the Week of November 25

The Center for Biosimilars® recaps the top stories for the week of November 25, 2019.
November 29, 2019



Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 25, 2019.

Number 5: Could there be trouble ahead for Alexion? A Roche subsidiary has claimed that the drug maker infringed on its patent for a technology that extends the half-lives of antibodies.

Number 4: Studies of single-agent immune checkpoint inhibitors in ovarian cancer have shown limited activity, but combination therapy with bevacizumab may hold promise.

Number 3: Researchers report that an unfolding microneedle injector could be a feasible delivery device for biologic drugs like insulin.

Number 2: A new study from the Nordic region shows similar retention rates for patients who start treatment with reference or biosimilar infliximab or etanercept.  

Number 1: Data presented during the European Society for Medical Oncology Asia Congress 2019, held last week in Singapore, support the biosimilarity of HLX02 and Herceptin.

Finally, last week, our e-newsletter asked whether you think that we will continue to see more relatively deep discounts on biosimilars’ list prices after Ziextenzo launched at a 37% discount.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.